biostudies-literatureHuffman BMStand Up To CancerBreakthrough CancerNational Cancer InstituteLustgarten FoundationNCI NIH HHSHale Family Center for Pancreatic Cancer Research5047-5056https://www.ebi.ac.uk/biostudies/studies/S-EPMC10842136biostudies-literatureUnknown29(24)<h4>Purpose</h4>Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448) investigating low-dose gemcitabine combined with the CHK1 inhibitor LY2880070 in patients with previously treated advanced PDAC.<h4>Patients and methods</h4>Patients with metastatic PDAC were treated with gemcitabine intravenously at 100 mg/m2 on days 1, 8, and 15, and LY2880070 50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle. Pretreatment tumor biopsies were obtained from each patient for correlative studies and generation of organoid cultures for drug sensitivity testing and biomarker analyses.<h4>Results</h4>Eleven patients with PDAC were eClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.PMC10842136P30 CA006516P50CA127003P50 CA127003Sadatrezaei GDunwell SAndrews EWang JGetchell ZRaghavan SPerez KJShapiro GISingh HHuffman BMKapner KSRubinson DASchlechter BLAguirre AJNg KHannigan AMAbrams TAGiannakis MFortier CKochupurakkal BPatel AKD'Andrea ADWolpin BMFeng HCleary JMParmar KBiller LHMartignetti DBfalseA Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.<h4>Purpose</h4>Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448) investigating low-dose gemcitabine combined with the CHK1 inhibitor LY2880070 in patients with previously treated advanced PDAC.<h4>Patients and methods</h4>Patients with metastatic PDAC were treated with gemcitabine intravenously at 100 mg/m2 on days 1, 8, and 15, and LY2880070 50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle. Pretreatment tumor biopsies were obtained from each patient for correlative studies and generation of organoid cultures for drug sensitivity testing and biomarker analyses.<h4>Results</h4>Eleven patients with PDAC were e2023-01-01T00:00:00Z2023 Dec2026-05-29T17:08:32.341Z2026-04-08T05:27:55.968ZS-EPMC108421363781993610.1158/1078-0432.CCR-23-200510.1158/1078-0432.ccr-23-2005